LATISSE

This brand name is authorized in Brazil, Canada, New Zealand, United States

Active ingredients

The drug LATISSE contains one active pharmaceutical ingredient (API):

1 Bimatoprost UNII QXS94885MZ - BIMATOPROST

Bimatoprost is a potent ocular hypotensive agent. It is a synthetic prostamide, structurally related to prostaglandin F2α (PGF2α), that does not act through any known prostaglandin receptors. Read about Bimatoprost

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LATISSE Eyes drops, solution	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
S01EE03	Bimatoprost	S Sensory organs → S01 Ophthalmologicals → S01E Antiglaucoma preparations and miotics → S01EE Prostaglandin analogues
Discover more medicines within S01EE03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 501006901131310
Country: CA	Health Products and Food Branch	Identifier(s): 02350939
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 13943
Country: US	FDA, National Drug Code	Identifier(s): 0023-3616